Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency
Authors: Peter A. Ljubenkov, Lauren Edwards, Leonardo Iaccarino, Renaud La Joie, Julio C. Rojas, Mary Koestler, Baruch Harris, Bradley F. Boeve, Barbara Borroni, John C. van Swieten, Murray Grossman, Florence Pasquier, Giovanni B. Frisoni, Catherine J. Mummery, Rik Vandenberghe, Isabelle Le Ber, Didier Hannequin, Scott M. McGinnis, Sophie Auriacombe, Marco Onofrj, Ira J. Goodman, Henry J. Riordan, Gary Wisniewski, Jacob Hesterman, Ken Marek, Beth Ann Haynes, Holger Patzke, Gerhard Koenig, Dana Hilt, Hans Moebius, Adam L. Boxer
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Histone deacetylase inhibitors have been repeatedly shown to elevate progranulin levels in preclinical models. This report describes the first randomized clinical trial of a histone deacetylase inhibitor in frontotemporal dementia (FTD) resulting from progranulin (<i>GRN</i>) gene variations. <h3>Objective</h3> To characterize the safety, tolerability, plasma pharmacokinetics, and pharmacodynamic effects of oral FRM-0334 on plasma progranulin and other exploratory biomarkers, including fluorodeoxyglucose (FDG)–positron emission tomography (PET), in individuals with<i>GRN</i>haploinsufficiency. <h3>Design, Setting, and Participants</h3> In this randomized, double-blind, placebo-controlled, dose-escalating, phase 2a safety, tolerability, and pharmacodynamic clinical study, 2 doses of a histone deacetylase inhibitor (FRM-0334) were administered to participants with prodromal to moderate FTD with granulin variations. Participants were recruited from January 13, 2015, to April 13, 2016. The study included 27 participants with prodromal (n = 8) or mild-to-moderate symptoms of FTD (n = 19) and heterozygous pathogenic variations in<i>GRN</i>and was conducted at multiple centers in North America, the UK, and the European Union. Data were analyzed from June 9, 2019, to May 13, 2021. <h3>Interventions</h3> Daily oral placebo (n = 5), 300 mg of FRM-0334 (n = 11), or 500 mg of FRM-0334 (n = 11) was administered for 28 days. <h3>Main Outcomes and Measures</h3> Primary outcomes were safety and tolerability of FRM-0334 and its peripheral pharmacodynamic effect on plasma progranulin. Secondary outcomes were the plasma pharmacokinetic profile of FRM-0334 and its pharmacodynamic effect on cerebrospinal fluid progranulin. Exploratory outcomes were FDG-PET, FTD clinical severity, and cerebrospinal fluid biomarkers (neurofilament light chain [NfL], amyloid β 1-42, phosphorylated tau 181, and total tau [t-tau]). <h3>Results</h3> A total of 27 participants (mean [SD] age, 56.6 [10.5] years; 16 women [59.3%]; 26 White participants [96.3%]) with<i>GRN</i>variations were randomized and completed treatment. FRM-0334 was safe and well tolerated but did not affect plasma progranulin (4.3 pg/mL per day change after treatment; 95% CI, –10.1 to 18.8 pg/mL;<i>P</i> = .56), cerebrospinal fluid progranulin (0.42 pg/mL per day; 95% CI, –0.12 to 0.95 pg/mL;<i>P</i> = .13), or exploratory pharmacodynamic measures. Plasma FRM-0334 exposure did not increase proportionally with dose. Brain FDG-PET data were available in 26 of 27 randomized participants. In a cross-sectional analysis of 26 individuals, bifrontal cortical FDG hypometabolism was associated with worse Clinical Dementia Rating (CDR) plus National Alzheimer's Coordinating Center frontotemporal lobar degeneration sum of boxes score (b = −3.6 × 10<sup>−2</sup>standardized uptake value ratio [SUVR] units/CDR units; 95% CI, −4.9 × 10<sup>−2</sup>to −2.2 × 10<sup>−2</sup>;<i>P</i> &lt; .001), high cerebrospinal fluid NfL (b = −9.2 × 10<sup>−5</sup>SUVR units/pg NfL/mL; 95% CI, −1.3 × 10<sup>−4</sup>to −5.6 × 10<sup>−5</sup>;<i>P</i> &lt; .001), and high CSF t-tau (−7.2 × 10<sup>−4</sup>SUVR units/pg t-tau/mL; 95% CI, −1.4 × 10<sup>−3</sup>to −9.5 × 10<sup>−5</sup>;<i>P</i> = .03). <h3>Conclusions and Relevance</h3> In this randomized clinical trial, the current formulation of FRM-0334 did not elevate PRGN levels, which could reflect a lack of efficacy at attained exposures, low bioavailability, or some combination of the 2 factors. Bifrontal FDG-PET is a sensitive measure of symptomatic<i>GRN</i>haploinsufficiency. International multicenter clinical trials of FTD-GRN are feasible. <h3>Trial Registration</h3> ClinicalTrials.gov Identifier:NCT02149160